22,66 €
Deine Einschätzung
Intellia Therapeutics Inc Aktie
Was spricht für und gegen Intellia Therapeutics Inc in den nächsten Jahren?
Pro
Kontra
Rendite von Intellia Therapeutics Inc im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Intellia Therapeutics Inc | -1,69 % | -2,54 % | 1,77 % | -40,85 % | -20,38 % | -82,21 % | 51,74 % |
VBI Vaccines Inc. | -9,26 % | -15,42 % | 10,74 % | -54,70 % | 12,83 % | -99,22 % | -96,99 % |
Organovo Holdings Inc. | -3,28 % | -11,47 % | -27,42 % | -67,99 % | -46,59 % | -91,92 % | -93,86 % |
Matinas BioPharma Holdings Inc | 4,76 % | 5,50 % | 11,34 % | -47,82 % | -19,95 % | -75,75 % | - |
Kommentare
News
![The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger: https://g.foolcdn.com/editorial/images/782323/researchers-work-in-the-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN2JPYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e2f5f99c23dd7e2d5e9606d31ddf2749c32a4fbf/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/researchers-work-in-the-lab.jpg?locale=de)
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
Intellia Therapeutics (NASDAQ: NTLA) just published some new data that suggests the company has what it takes to continue being a leader in the gene editing space. While there's still a lot of work
![Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought: https://g.foolcdn.com/editorial/images/779964/gettyimages-998452928.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNml6YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--41539f874dd02edc3da80f408d7f3074cebb6134/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-998452928.jpg?locale=de)
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
Cathie Wood is known for two things: picking out innovators that will go on to score a win over the long run, and getting in on these stocks at a great price. The founder and chief executive officer
![These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now: https://g.foolcdn.com/editorial/images/779725/group-of-scientists-with-microscopes-lab-testing1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMEd6YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d6192b99846efdce6b74d6a5354d4fe079cccc53/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/group-of-scientists-with-microscopes-lab-testing1.jpg?locale=de)
These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now
On June 2, Intellia Therapeutics' (NASDAQ: NTLA) CEO John Leonard remarked on the biotech's progress with one of its early-stage clinical programs called NTLA-2002, uttering two very important words